Literature DB >> 1098864

Mode of action of 5-fluorocytosine and mechanisms of resistance.

A Polak, H J Scholer.   

Abstract

Mode of action of 5-fluorocytosine (5-FC) and mechanisms of resistance to the drug are discussed on the basis of experiments performed with Candida albicans ATCC 26790 and with 50 selected clinical isolates of C. albicans belonging to serological type A or B and representing various degrees and models of 5-FC resistance (sensitivity). Incorporation of 5-fluorouridylic acid into RNA appeared as a prerequisite to antifungal activity, although at a given incorporation rate, growth inhibition varied considerably from one strain to the other. The amino acid pool was unbalanced, and there was evidence for disturbance of protein synthesis. These dysfunctions of RNA probably account for growth inhibition and cell death, whereas up to the present, there was no proof of formation of 5-fluorodeoxyuridylic acid nor of subsequent inhibition of thymidylate synthetase. Incorporation of fluorinated pyrimidine into RNA was lower in normally sensitive type B strains than in normally sensitive ones of type A, whereas the frequency of 5-FC-resistant mutants was the same. The two serological types did not differ in the activity of cytosine permease nor in that of cytosine deaminase. Among 29 clinical isolates with 6-FC resistance (or impaired sensitivity) no instance of cytosine permease deficiency was found. Two isolates (belonging to the serological type A) were deficient in cytosine deaminase, whereas the majority was probably deficient in uridine monophosphate pyrophosphorylase or had a surplus of de novo synthesis of pyrimidines. Relative 5-FC resistance was more common than complete resistance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1098864     DOI: 10.1159/000221854

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  56 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 5.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.

Authors:  C A Mullen; M Kilstrup; R M Blaese
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

7.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Histone acetyltransferase Rtt109 is required for Candida albicans pathogenesis.

Authors:  Jessica Lopes da Rosa; Victor L Boyartchuk; Lihua Julie Zhu; Paul D Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  A 19F nuclear magnetic resonance study of uptake and metabolism of 5-fluorocytosine in susceptible and resistant strains of Candida albicans.

Authors:  M Di Vito; F Podo; A Torosantucci; G Carpinelli; W L Whelan; D Kerridge; A Cassone
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

10.  Flucytosine for treatment of Candida albicans in H1N1-positive patient.

Authors:  Tanvir Samra; Amlendu Yadav; Neerja Banerjee; Mridula Pawar; Desh Deepak
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.